Nadravaleucel

Ewing Sarcoma

Brenda Cooper, MDCell therapyPhase 2Dormant

B

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 44/ 100
Competitive Position: 81/ 100

Competitive context

57 Active assets in the Ewing Sarcoma cohort.

Asset / Sponsor	Phase	Rating
Irinotecan Milton S. Hershey Medical Center	Phase 3	BB
Nivolumab Children's National Research Institute	Phase 2	B
Cyclophosphamide Essen Biotech	Phase 2	B
Adriamycin Children's National Research Institute	Phase 2	B
Nogitecan Pfizer	Phase 2	B

View all 50 →

Same molecule, other indications

Nadravaleucel is also rated in:

central nervous system neoplasmDormant

B

Indicative · Phase 2

61 / 100

non-Hodgkin lymphomaActive

B

Indicative · Phase 2

59 / 100

myelodysplastic syndromeActive

B

Indicative · Phase 2

58 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.